June 26, 2019 09:08 AM EDTUpdated 11:03 AM
News Briefing

Ox­ford Bio­med­ica, San­ten ink gene ther­a­py pact; DayT­wo rais­es $31M in Se­ries B round

Natalie Grover

Reporter

→ British gene and cell ther­a­py com­pa­ny Ox­ford Bio­med­ica {LSE: $OXB} is join­ing forces with Japan’s San­ten Phar­ma­ceu­ti­cal to de­vel­op gene ther­a­pies for in­her­it­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times